Printed From BioPortfolio.com
Abcam acquires rights to over 700 Roche products in new licensing deal
05:59 EST 22 Jan 2018 | Pharmafile
Roche has entered a licensing agreement Abcam which gives the British biotech exclusive access to the marketing rights for 760 of the Swiss pharma giant’s products, all of which are for research use only (RUO).
The full range of products represents the complete portfolio of Spring Bioscience Corporation, a California-based biotech that Roche acquired in 2007, and includes 243 antibodies for use in rabbits, in addition to more than 500 other antibodies.
Original Article: Abcam acquires rights to over 700 Roche products in new licensing deal
